[新时代:从GLP-1受体激动剂到共激动剂和多激动剂]
1Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Liège, ULiège, Belgique.
Revue medicale de Liege
|September 12, 2024
概括
双GIP/GLP-1激动剂,如蒂尔泽帕提德,可改善2型糖尿病 (T2D) 的血糖控制和减肥. 未来的多动因药剂也可以治疗肥胖和肝硬化症.
科学领域:
- 糖尿病学 糖尿病学
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 胰岛素激素,葡萄糖类-1 (GLP-1) 和依赖葡萄糖的胰岛素托普多 (GIP),是2型糖尿病 (T2D) 管理的关键.
- GLP-1受体激动剂是T2D的确立治疗方法,改善血糖控制,促进体重减轻,并提供心血管和脏保护.
- 针对GIP和GLP-1受体的新兴协同激素剂代表了重要的治疗进步.
研究的目的:
- 审查基于英克雷丁的疗法在2型糖尿病管理中的作用.
- 突出GIP/GLP-1双抗原剂的开发和有效性,如蒂尔泽帕提德.
- 讨论未来的多抗激素剂 (GIP/GLP-1/GCG) 对代谢并发症的潜力.
主要方法:
- 对临床试验数据的审查,重点是针对蒂尔泽帕提德的SURPASS计划.
- 对单抗,双抗和多抗激素剂的药理机制的分析.
- 综合了目前关于基于隐素的疗法及其对T2D和相关疾病的影响的文献.
主要成果:
- 蒂尔泽帕提德是一种双GIP/GLP-1激动剂,与以前的疗法相比,在T2D患者中表现出优异的葡萄糖控制.
- 虽然GIP/GLP-1联合输注与单独的GLP-1相比显示出有限的额外益处,但像蒂尔泽帕提德这样的单分子双激动剂提供了显著的改善.
- 目前正在开发GLP-1/葡萄糖 (GCG) 和GIP/GLP-1/GCG多激素剂,它们可能为能量消耗和肝脏新陈代谢带来更大的好处.
结论:
- 双重GIP/GLP-1激动剂,以蒂尔泽帕提德为例,在治疗2型糖尿病方面非常有效.
- 未来的基于英克雷丁的疗法,包括多活性激剂,对治疗肥胖和代谢并发症如T2D和肝硬化等有前途.
- 印克雷受体激活剂的进化继续为代谢性疾病提供新的治疗途径.
更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K


